161.50 +3.13 (1.98%)
Pre-Market: 8:21AM EDT
|Bid||161.22 x 1200|
|Ask||161.40 x 300|
|Day's Range||157.69 - 164.80|
|52 Week Range||123.73 - 192.15|
|PE Ratio (TTM)||11.28|
|Forward Dividend & Yield||1.05 (0.64%)|
|1y Target Est||197.42|
Let's check out the Yahoo Finance charts of the day. Texas Instruments (TXN): Shares are higher in early trade, up around 3%. The chipmaker reported adjusted quarterly profit of $1.21 per share, 10 cents a share above consensus forecasts. The company also forecast stronger than expected earnings for the current quarter. Shire (SHPG): Shares down around 0.52%. The biopharmaceutical company said it was willing to recommend the latest takeover bid from Japan's Takeda Pharmaceutical, after rejecting four other bids, Takeda is now offering $64 billion for the British drug maker. Wynn Resorts (WYNN): Shares slip down around 3.4%. The company posting adjusted quarterly earnings of $2.30 per share, beating estimates by 32 cents a share. The casino operator's revenue was slightly below forecasts. Wynn also increased it's quarterly dividend to 75 cents per share from 50 cents. For more on today's big stock movers check out The Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.
Shire (SHP.L), the London-listed drugmaker targeted by Takeda Pharmaceutical , reported a 6 percent rise in first-quarter earnings on Thursday, while keeping its cautious outlook for the year in the face of increasing drug competition. Shire is willing to recommend a $64 billion (46 billion pounds) offer from Takeda to shareholders, in what would be the biggest acquisition of a drug company since 2000, but investors see risks to the ambitious deal being consummated. Currency factors flattered Shire sales in the quarter as Shire felt the impact of falling sales of its flagship ulcerative colitis drug Lialda.
, the life sciences specialist currently considering a takeover proposal from Japan’s Takeda, saw overall sales rise by 7 per cent year-on-year in the first quarter on the back of immunology, recently-launched products and overseas expansion. The company, which has agreed a deadline of May 8 by which Takeda must make its intentions known under UK takeover rules, said sales had been $3.6bn in the first three months of this year. Mr Ornskov has set a goal of between $17bn and $18bn in annual sales by 2020.
Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018 Growth driven by Immunology, recently-launched products, and international expansion Innovative pipeline progresses ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...
Takeda is near a deal worth more than $60 billion to buy European drugmaker Shire, having raised its bid four times in a sign of how ardently Japan’s legacy companies are pursuing growth abroad as sales ...
Shire said late Tuesday it's willing to recommend a $64 billion takeover by Takeda Pharmaceuticals to shareholders before a new May 8 deadline.
Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest. After three of Takeda’s previous bids were rejected, it announced a new bid of $60 billion for Shire on April 20. Takeda, a Japanese pharmaceutical company, has increased its offer to 47 pounds per share from 46.5 pounds per share.
Moody's Investors Service commented that an acquisition of Shire plc ("Shire") by Takeda Pharmaceutical Company Limited ("Takeda") could have either positive or negative implications for Shire's credit profile. Shire is rated Baa3 with a positive rating outlook. There is no impact on Shire's ratings or outlook at this time.
LONDON/NEW YORK/TOKYO (Reuters) - Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000. The stock slide - 18 percent since the news of a possible bid broke - makes the cash-and-share deal less appealing to Shire shareholders, some of whom may be reluctant or unable to hold Takeda shares. "The chances are UK shareholders in particular are not going to want Takeda shares, so there’s going to be a forced discount because some people are going to sell it," said Neil Dwane, global strategist at Allianz Global Investors, which holds 1.1 percent of Shire, Thomson Reuters data showed.